Exelixis Initiates P-III COSMIC-313 Study of Triple Combination Therapy for Advanced Renal Cell Carcinoma

 Exelixis Initiates P-III COSMIC-313 Study of Triple Combination Therapy for Advanced Renal Cell Carcinoma

Exelixis Initiates P-III COSMIC-313 Study of Triple Combination Therapy for Advanced Renal Cell Carcinoma

Shots:

  • The P-III COSMIC-313 study involves assessing of Cabometyx (cabozantinib) + Opdivo (nivolumab) + Yervoy (ipilimumab) vs nivolumab+ ipilimumab + PBO in 676 patients in the ratio (1:1) with previously untreated advanced RCC across 150 sites globally
  • The P-III COSMIC-313 study follows ongoing P-Ib study assessing cabozantinib + nivolumab with/without ipilimumab in patients with advanced genitourinary cancers including RCC, previously treated with sorafenib
  • Cabometyx is a tyrosine kinase inhibitor promoting an immune-permissive environment in combination with immune checkpoint inhibitors and is approved in the US for HCC & advanced RCC. Opdivo & Yervoy are checkpoint inhibitors developed by BMS

Click here to read full press release/ article | Ref: Exelixis | Image: Brand Navigation

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post